Hiroko Iijima
A5061999363- Liver Disease Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease and Transplantation
- Nutrition and Health in Aging
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Ultrasound and Hyperthermia Applications
- Pancreatic and Hepatic Oncology Research
- Liver Diseases and Immunity
- Colorectal Cancer Treatments and Studies
- Algal biology and biofuel production
- Cancer, Lipids, and Metabolism
- Body Composition Measurement Techniques
- Photosynthetic Processes and Mechanisms
- Ultrasound Imaging and Elastography
- Pancreatitis Pathology and Treatment
- Cancer Research and Treatments
- MRI in cancer diagnosis
- Organ Transplantation Techniques and Outcomes
- Microbial Community Ecology and Physiology
- Alcohol Consumption and Health Effects
- Immune Cell Function and Interaction
- Clinical Nutrition and Gastroenterology
- Radiomics and Machine Learning in Medical Imaging
Hyogo University
2008-2025
Tokyo Medical University
2001-2024
National Hospital Organization Takasaki Medical Center
2024
International University of Health and Welfare
2024
Assistance Publique – Hôpitaux de Paris
2024
Memorial Hospital
2024
Rocky Vista University
2024
National University
2024
Hôpital Beaujon
2024
Hyogo Medical University
2014-2023
The fourth version of Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society Hepatology, according to methodology evidence-based medicine and partly Grading Recommendations Assessment, Development, Evaluation system, which published in October 2017 Japanese. New or recommendations were described, herein, with a special reference surveillance, diagnostic, treatment algorithms.
Abstract Background We aimed to elucidate the relationship between serum myostatin levels and other markers including skeletal muscle mass investigate influence of on survival for patients with liver cirrhosis (LC). Methods A total 198 LC subjects were analysed in this study. Myostatin measured using stored sera. retrospectively investigated level markers, overall (OS). Assessment was performed psoas index (PMI) computed tomography images at baseline. PMI indicates sum bilateral calculated...
The fifth version of the Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by Japan Society Hepatology, according to methodology evidence-based medicine and partly Grading Recommendations Assessment, Development Evaluation system, which published in October 2021 Japanese. In addition surveillance-diagnostic treatment algorithms, a new algorithm systemic therapy has been created, as multiple drugs hepatocellular carcinoma can be currently selected. Here, or algorithms...
A growing body of evidence suggests that non-viral hepatocellular carcinoma (HCC) might benefit less from immunotherapy.We carried out a retrospective analysis prospectively collected data consecutive patients with advanced HCC, treated atezolizumab plus bevacizumab, lenvatinib, or sorafenib, in 36 centers 4 countries (Italy, Japan, Republic Korea, and UK). The primary endpoint was overall survival (OS) bevacizumab versus lenvatinib. Secondary endpoints were progression-free (PFS) OS PFS...
The World Federation for Ultrasound in Medicine and Biology (WFUMB) has promoted the development of this document on multiparametric ultrasound. Part 2 is a guidance use available tools quantification liver fat content with These are attenuation coefficient, backscatter speed sound. All them raw data ultrasound beam to estimate content. This aim helping reader understanding how they work interpret results. Confounding factors discussed standardized protocol measurement acquisition suggested...
<i>Objective:</i> To evaluate the diagnostic accuracy of liver cirrhosis by imaging modalities, including CT, MRI and US, compared to results obtained from histopathological diagnoses resected specimens. <i>Materials Methods:</i> US examinations 142 patients with chronic disease who underwent surgery for complicated hepatocellular carcinoma (<3 cm in diameter) 10 institutions were blindly reviewed a multicenter study three radiologists experienced US. The images...
Because cyanobacteria directly harvest CO2 and light energy, their carbon metabolism is important for both basic applied sciences. Here, we show that overexpression of the sigma factor sigE in Synechocystis sp. PCC 6803 widely changes sugar catabolism increases production biodegradable polyester polyhydroxybutyrate (PHB) during nitrogen starvation. elevates levels proteins implicated glycogen catabolism, oxidative pentose phosphate pathway, polyhydroxyalkanoate biosynthesis. PHB accumulation...
The first edition of the guidelines for use ultrasound contrast agents was published in 2004, dealing with liver applications. second 2008 reflected changes available and updated liver, as well implementing some nonliver third contrast-enhanced (CEUS) joint World Federation Ultrasound Medicine Biology-European Societies Biology (WFUMB-EFSUMB) venture conjunction other regional US societies such Asian Biology, resulting a simultaneous duplicate on CEUS official journals both WFUMB EFSUMB...
Abstract Background Although atezolizumab plus bevacizumab (Atez/bev) treatment has been developed for unresectable hepatocellular carcinoma (u‐HCC), changes in hepatic function during therapy have yet to be reported. Aim This retrospective clinical study aimed elucidate early responses Atez/Bev. Methods From September 2020 April 2021, 171 u‐HCC patients undergoing Atez/Bev were enrolled (BCLC stage A:B:C:D = 5:68:96:2). Of those, 75 had no prior history of systemic treatment. Relative and...
Atezolizumab plus bevacizumab (Atez/Bev) treatment is recommended for unresechepatocellular carcinoma (u-HCC) patients classified as Child-Pugh A (CP-A). This study aimed to elucidate the prognosis of treated with Atez/Bev, especially CP-A and -B cases.From September 2020 March 2022, 457 u-HCC Atez/Bev were enrolled (median age 74 years, male:female = 368:89, CP-A:CP-B 427:30, score [CPS] 5:6:7:8:9 271:156:21:8:1). Therapeutic response was evaluated using RECIST ver.1.1. Clinical features...
To investigate whether neutrophil-to-lymphocyte ratio (NLR) can predict outcomes in patients with unresectable hepatocellular carcinoma (HCC) treated atezolizumab plus bevacizumab (Atez/Bev).A total of 249 HCC Atez/Bev were included. We analyzed survival and discontinuation this therapy cohort.Cumulative overall at 2, 4, 6, 8 months was 97.6%, 94.9%, 88.9%, 82.8%, respectively. Cumulative differed significantly between low (<3.0) versus high (≥3.0) NLR (P = 0.001). Conversely, cumulative...
Ultrasonography (US) is widely used for the diagnosis of liver tumors. However, accuracy largely depends on visual perception humans. Hence, we aimed to construct artificial intelligence (AI) models tumors in US.We constructed three AI based still B-mode images: model-1 using 24,675 images, model-2 57,145 and model-3 70,950 images. A convolutional neural network was train US The four-class tumor discrimination by AI, namely, cysts, hemangiomas, hepatocellular carcinoma, metastatic tumors,...
The aim of this retrospective proof-of-concept study was to compare different second-line treatments for patients with hepatocellular carcinoma and progressive disease (PD) after first-line lenvatinib or atezolizumab plus bevacizumab.A total 1381 had PD at therapy. 917 received as treatment, 464 bevacizumab first-line.49.6% a therapy without any statistical difference in overall survival (OS) between (20.6months) (15.7months; p = 0.12; hazard ratio [HR]= 0.80). After first-line, there wasn't...
Introduction: Lack of an established methodology for post-progression systemic treatment following atezolizumab plus bevacizumab (Atez/Bev) administration is important clinical issue. The present study aimed to elucidate the potential lenvatinib as a second-line option after Atez/Bev failure. Methods: From 2020 2022, 101 patients who received were enrolled (median 72 years, males 77, Child-Pugh A 82, BCLC-A:B:C:D = 1:35:61:4), while 29 treated with another molecular targeting agent (MTA)...